Verona Pharma plc
VRNA
Rangering i aksjer
#2232
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Aksjekurs
$106.91
Sist synkronisert: 2025-10-07
Markedsverdi
$9.09B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
GB
Handel Verona Pharma plc (VRNA)
Kategori
Healthcare
Historikk for aksjesplitt for Verona Pharma plc (VRNA)
Aksjen Verona Pharma plc (symbol: VRNA) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én VRNA-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 VRNA-aksjer.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én VRNA-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 VRNA-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
